In Clinical news

Follow this topic

Bookmark

Record learning outcomes

The MHRA has updated its guidance for patients on using GLP-1 receptor agonists for weight loss just days after Lilly announced a huge price hike for Mounjaro leading to significant supply chain disruption.

The medicines, including semaglutide (Ozempic, Rybelsus and Wegovy), liraglutide and tirzepatide (Mounjaro), remain prescription-only for type 2 diabetes and weight management in line with NICE criteria.

The regulator warns against cosmetic use and unregulated online sales, which may involve fake or contaminated pens.

There is specific advice on switching preparations. “Before switching from one GLP-1 medicine to another, including between brands containing the same type of GLP-1, you should consult a healthcare professional for advice,” the guidance states.

“Switching without medical advice may increase the risk of experiencing side-effects or make the treatment less effective.”

Other key safety reminders include contraceptive precautions with tirzepatide, risks linked to delayed gastric emptying before surgery, monitoring for pancreatitis and correct disposal of pens. 

Earlier this week, new draft guidelines from NICE proposed adults with cardiovascular disease should be offered triple therapy including a GLP-1 receptor agonist.

The medication class should also be considered for adults with early onset type 2 diabetes diagnosed before 40 years of age.

Also read: Mounjaro price hike ‘will drive more patients to black market

NHS diabetes budget soars as Mounjaro spend up 340-fold